Clinical Aspects of Tumor necrosis factor-α signaling in hepatocellular carcinoma

Current Pharmaceutical Design

Volumn 20, Issue 17, 2014, Pages 2799-2808

  Jang, Myoung Kuk ^a   Kim, Hyoung Su ^a   Chung, Young Hwa ^b  

^a Hallym University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Anti cancer therapy; Hepatocarcinogenesis; Hepatocellular carcinoma; Single nucleotide polymorphism; Tumor necrosis factor alpha

Indexed keywords

CASPASE 8; CYTOCHROME C; EPIDERMAL GROWTH FACTOR; I KAPPA B ALPHA; I KAPPA B BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; NONSTRUCTURAL PROTEIN 5A; SCATTER FACTOR; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT;

ALCOHOLIC FATTY LIVER; APOPTOSIS; BLOOD VESSEL PERMEABILITY; CELL PROLIFERATION; CHRONIC HEPATITIS; CYTOKINE PRODUCTION; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER REGENERATION; LONG TERM EXPOSURE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; VIRUS HEPATITIS; BIOLOGICAL MODEL; CARCINOMA, HEPATOCELLULAR; CELL DEATH; CELL TRANSFORMATION; DRUG EFFECTS; LIVER NEOPLASMS; METABOLISM; PRECANCER;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL DEATH; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MODELS, BIOLOGICAL; PRECANCEROUS CONDITIONS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84903744344     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990587     Document Type: Review

References (146)

1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666-70.
2. Shirai T, Yamaguchi H, Ito H, Todd CW, Wallace RB. Cloning and expression in Escherichia coli of the gene for human tumor necrosis factor. Nature 1985; 313: 803-6.
3. MacEwan DJ. TNF receptor subtype signaling: differences and cellular consequences. Cell Signal 2002; 14: 477-92.
4. Bemelmans MH, van Tits LJ, Buurman WA. Tumor necrosis factor: function, release and clearance. Crit Rev Immunol 1996; 16: 1-11.
5. González-Amaro R, García-Monzón C, García-Buey L, et al. Induction of tumor necrosis factor alphaproduction by humanhepatocytes in chronicviralhepatitis. J Exp Med 1994; 179: 841-8.
6. McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 1989; 9: 349-51.
7. Diehl AM. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 619-38.
8. Arii S, Teramoto K, Kawamura T. Current progress in the understanding and therapeutic strategies for ischemia and reperfusion injury of the liver. J Hepatobiliary Pancreat Surg 2003; 10: 189-94.
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
10. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-16.
11. Kim SR, Kudo M, Hino O, Han KH, Chung YH, Lee HS; Organizing Committee of Japan-Korea Liver Symposium. Epidemiology of hepatocellular carcinoma in Japan and Korea. A review. Oncology 2008; 75: S13-6.
12. Chung YH. Systemic anticancer therapy for hepatocellular carcinima. 1st ed. Jin Publishing Co. 2011.
13. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol 2005; 23: 2892-9.
14. Park NH, Song IH, Chung YH. Molecular pathogenesis of hepatitis-B-virus-associated hepatocellular carcinoma. Gut and Liver 2007; 1: 101-17.
15. Park IY, Sohn BH, Yu E, et al. Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology 2007; 132: 1476-94.
16. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-46.
17. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003; 10: 45-65.
18. Mannel DN, Echtenacher B. TNF in the inflammatory response. Chem Immunol 2000; 74: 141-61.
19. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002; 296: 1634-5.
20. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003; 114: 181-90.
21. Schwabe RF, Brenner DA. Mechanisms of Liver Injury. I. TNFalpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol 2006; 290: G583-9.
22. Schwabe RF, Brenner DA. Nuclear factor-kappaB in the liver: friend or foe? Gastroenterology 2007; 132: 2601-4.
23. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280-8.
24. Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007; 356: 1545-59.
25. Michalopoulos GK. Liver regeneration. J Cell Physiol 2007; 213: 286-300.
26. Taub R. Liver regeneration: from myth to mechanism. Nature 2004; 5; 836-47.
27. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006; 12: 410-6.
28. Fausto N. Liver regeneration. J Hepatol 2000; 32: S19-31.
29. Cha C, Dematteo RP. Molecular mechanisms in hepatocellular carcinoma development. Best Pract Res Clin Gastroenterol 2005; 19: 25-37
30. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.
31. Singh M, Kumar V. Transgenic mouse models of hepatitis B virusassociated hepatocellular carcinoma. Rev Med Virol 2003; 13: 243-53
32. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-50.
33. Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004; 127: S56-61
34. Szlosarek PW, Balkwill FR. Tumor necrosis factor alpha: a potential target for the therapy of solid tumors. Lancet Oncol 2003; 4: 565-73.
35. Noach LA, Bosma NB, Jansen J, Hoek FJ, van Deventer SJ, Tytgat GN. Mucosal tumor necrosis factor-α, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol 1994; 29: 425-9.
36. Noguchi M, Hiwatashi N, Liu Z, Toyota T. Secretion imbalance between tumor necrosis factor and its inhibitor in inflammatory bowel disease. Gut 1998; 43: 203-9.
37. Chaisson ML, Brooling JT, Ladiges W, Tsai S, Fausto N. Hepatocyte-specific inhibition of NF-kappaB leads to apoptosis after TNF treatment, but not after partial hepatectomy. J Clin Invest 2002; 110: 193-202.
38. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121: 977-90.
39. Schwabe RF, Bradham CA, Uehara T, et al. c-Jun-N-terminal kinase drives cyclin D1 expression and proliferation during liver regeneration. Hepatology 2003; 37: 824-32.
40. Roberts RA, Nebert DW, Hickman JA, Richburg JH, Goldsworthy TL. Perturbation of the mitosis/apoptosis balance: a fundamental mechanism in toxicology. Fundam Appl Toxicol 1997; 38: 107-15
41. Pitot HC. Hepatocyte death in hepatocarcinogenesis. Hepatology 1998; 28: 1-5.
42. Yamada Y, Fausto N. Deficient liver regeneration after carbon tetrachloride injury in mice lacking type 1 but not type 2 tumor necrosis factor receptor. Am J Pathol. 1998; 152: 1577-89.
43. Yamada Y, Kirillova I, Peschon JJ, Fausto N. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci USA. 1997; 94: 1441-6.
44. Roberts RA, Kimber I. Cytokines in non-genotoxic hepatocarcinogenesis. Carcinogenesis 1999; 20: 1397-401.
45. Balkwill F. Tumor necrosis factor and cancer. Nat Rev Cancer 2009; 9: 361-71.
46. Popivanova BK, Kitamura K, Wu Y, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008; 118: 560-70.
47. Kulbe H, Thompson R, Wilson JL, et al. The inflammatory cytokine tumor necrosis factor alpha generates an autocrine tumorpromoting network in epithelial ovarian cancer cells. Cancer Res 2007; 67: 585-92.
48. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancerrelated inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30: 1073-81.
49. Szlosarek P, Charles KA, Balkwill FR. Tumor necrosis factoralpha as a tumor promoter. Eur J Cancer 2006; 42: 745-50.
50. Knight B, Yeoh GC, Husk KL, et al. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med 2000; 192: 1809-18.
51. Kitakata H, Nemoto-Sasaki Y, Takahashi Y, Kondo T, Mai M, Mukaida N. Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Res 2002; 62: 6682-7.
52. Harrison ML, Obermueller E, Maisey NR, et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 2007; 25: 4542-9.
53. Brown ER, Charles KA, Hoare SA, et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol 2008; 19: 1340-6.
54. Larkin JM, Ferguson TR, Pickering LM, et al. A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. Br J Cancer 2010; 103: 1149-53.
55. Seki S, Nakashima H, Nakashima M, Kinoshita M. Antitumor immunity produced by the liver Kupffer cells, NK cells, NKT cells, and CD8 CD122 T cells. Clin Dev Immunol 2011; doi: 10.1155/2011/868345. Epub 2011 Nov 29.
56. Takahashi M, Ogasawara K, Takeda K, et al. LPS induces NK1.1+ alpha beta T cells with potent cytotoxicity in the liver of mice via production of IL-12 from Kupffer cells. J Immunol 1996; 156: 2436-42.
57. Kawarabayashi N, Seki S, Hatsuse K, et al. Decrease of CD56(+)T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma. Hepatology 2000; 32: 962-9.
58. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004; 127: S87-96.
59. Nath B, Szabo G. Alcohol-induced modulation of signaling pathways in liver parenchymal and nonparenchymal cells: implications for immunity. Semin Liver Dis 2009; 29: 166-77.
60. Beier JI, Luyendyk JP, Guo L, von Montfort C, Staunton DE, Arteel GE. Fibrin accumulation plays a critical role in the sensitization to lipopolysaccharide-induced liver injury caused by ethanol in mice. Hepatology 2009; 49: 1545-53.
61. Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut 2009; 58: 704-20.
62. Rao R. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. Hepatology 2009; 50: 638-44.
63. Nanji AA, Khettry U, Sadrzadeh SM, Yamanaka T. Severity of liver injury in experimental alcoholic liver disease. Correlation with plasma endotoxin, prostaglandin E2, leukotriene B4, and thromboxane B2. Am J Pathol 1993; 142: 367-73.
64. Yin M, Wheeler MD, Kono H, et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999; 117: 942-52.
65. O'Shea RS, Dasarathy S, McCullough AJ; Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology 2010; 51: 307-28.
66. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004; 127: S97-103.
67. Mennigen R, Nolte K, Rijcken E, et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G1140-9.
68. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-87.
69. Velayudham A, Dolganiuc A, Ellis M, et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009; 49: 989-97.
70. Seki E, De Minicis S, Osterreicher CH, et al. TLR4 enhances TGFbeta signaling and hepatic fibrosis. Nat Med 2007; 13: 1324-32.
71. Fox JG, Feng Y, Theve EJ, et al. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut 2010; 59: 88-97.
72. Dapito AH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012; 21: 04-16.
73. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
74. Lee WM. Hepatitis B Virus Infection. N Engl J Med 1997; 337: 1733-45.
75. Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2000; 15: E25-30.
76. Lee SH, Chung YH, Kim JA, et al. Histologic characteristics predisposing to development of hepatocellular carcinoma in patients with chronic hepatitis B. J Clin Pathol 2011; 64: 599-604
77. Lee D, Chung YH, Lee SH, et al. Biochemical Rather than Virologic Response to Interferon Therapy may be More Closely Associated with Decrease of Hepatocellular Carcinoma Incidence in Patients with Chronic Hepatitis B. Gut and Liver 2007; 1: 49-55.
78. Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998; 188: 341-50.
79. Matsubara K, Tokino T. Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. Mol Biol Med 1990; 7: 243-60.
80. Guidotti LG, Borrow P, Hobbs MV, et al. Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci USA 1996; 93: 4589-94.
81. Guidotti LG, Guilhot S, Chisari FV. Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and-independent pathways. J Virol 1994; 8: 1265-70.
82. Park NH, Song IH, Chung YH. Chronic hepatitis B in hepatocarcinogenesis. Postgrad Med J 2006; 82: 507-15.
83. Su F, Schneider RJ. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha. Proc Natl Acad Sci USA 1997; 94: 8744-9.
84. Fabregat I, Roncero C, Fernández M. Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int 2007; 27: 155-62.
85. Kim KH. Pro-apoptotic function of hepatitis B virus X protein. Korean J Hepatol 2010; 16: 112-22. [Korean]
86. Schattenberg JM, Schuchmann M, Galle PR. Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways. J Gastroenterol Hepatol 2011; 26: S213-9.
87. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29: 74-81.
88. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
89. Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 2004; 127: S62-71.
90. Nokta M, Matzke D, Jennings M, Schlick E, Nadler PI, Pollard R. In vivo administration of tumor necrosis factor-alpha is associated with antiviral activity in human peripheral mononuclear cells. Soc Exp Biol Med 1991; 197: 144-9.
91. Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992; 103: 264-74.
92. Larrea E, Garcia N, Qian C, Civeira MP, Prieto J. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996; 23: 210-7.
93. Majumder M, Ghosh AK, Steele R, et al. Hepatitis C virus NS5A protein impairs TNF-mediated hepatic apoptosis, but not by an anti-FAS antibody, in transgenic mice. Virology 2002; 294: 94-105.
94. Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002; 16: 185-94.
95. Perlemuter G, Lettéron P, Carnot F, et al. Alcohol and hepatitis C virus core protein additively increase lipid peroxidation and synergistically trigger hepatic cytokine expression in a transgenic mouse model. J Hepatol 2003; 39: 1020-7.
96. Hajeer AH, Hutchinson IV. Influence of TNFalpha gene polymorphisms on TNFalpha production and disease. Hum Immunol 2001; 62: 1191-9.
97. Hajeer AH, Hutchinson IV. TNF-alpha gene polymorphism: clinical and biological implications. Microsc Res Tech. 2000; 50: 216-28.
98. Kamizono S, Hiromatsu Y, Seki N, et al. A polymorphism of the 5' flanking region of tumour necrosis factor alpha gene is associated with thyroid-associated ophthalmopathy in Japanese. Clin Endocrinol (Oxf) 2000; 52: 759-64.
99. Soga Y, Nishimura F, Ohyama H, Maeda H, Takashiba S, Murayama Y. Tumor necrosis factor-alpha gene (TNF-alpha)-1031/-863,-857 single-nucleotide polymorphisms (SNPs) are associated with severe adult periodontitis in Japanese. J Clin Periodontol 2003; 30: 524-31
100. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195-9.
101. Higuchi T, Seki N, Kamizono S, et al. Polymorphism of the 5'-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens 1998; 51: 605-12.
102. Mestiri S, Bouaouina N, Ahmed SB, et al. Genetic variation in the tumor necrosis factor-a promoter region and in the stress protein hsp70-2: Susceptibility and prognostic implications in breast carcinoma. Cancer 2001; 91: 672-8.
103. Warzocha K, Ribeiro P, Bienvenu J, et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 1998; 91: 3574-81.
104. Oh BR, Sasaki M, Perinchery G, et al. Frequent genotype changes at-308, and 488 regions of the tumor necrosis factor-a (TNF-a) gene in patients with prostate cancer. J Urol 2000; 163: 1584-7.
105. Sasaki M, Nakajima K, Perinchery G, et al. Frequent genotype changes at-308 of the human tumor necrosis factor-alpha promoter region in human uterine endometrial cancer. Oncol Rep 2000; 7: 369-73.
106. Machado JC, Figueiredo C, Canedo P, et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003; 125: 364-71.
107. Kim YJ, Lee HS, Yoon JH, et al. Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet 2003; 12: 2541-6.
108. Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, Chen CJ. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology 1999; 29: 697-702.
109. Jin YJ, Shim JH, Chung YH, et al. Relationship of HLA-DRB1 Alleles With Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients. J Clin Gastroenterol 2012; 46: 420-6.
110. Lee SH, Chung YH, Kim JA, et al. Single nucleotide polymorphisms associated with metastatic tumour antigen 1 overexpression in patients with hepatocellular carcinoma. Liver Int 2012; 32: 457-66.
111. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
112. Kroeger KM, Carville KS, Abraham LJ. The-308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997; 34: 391-9.
113. Kummee P, Tangkijvanich P, Poovorawan Y, Hirankarn N. Association of HLA-DRB1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J Viral Hepat 2007; 14: 841-8.
114. Ho SY, Wang YJ, Chen HL, et al. Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the-308 tumor necrosis factor-alpha promoter gene. Cancer Causes Control 2004; 15: 657-63.
115. Jung KW, Ha E, Yu GI, et al. TNFalpha promoter polymorphism is a risk factor for susceptibility in hepatocellular carcinoma in Korean population. Clin Chim Acta 2009; 407: 16-9.
116. Jeng JE, Tsai JF, Chuang LY, et al. Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia 2007; 9: 987-92.
117. Akkiz H, Bayram S, Bekar A, et al. G-308A TNF-alpha polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: case-control study. Cancer Epidemiol 2009; 33: 261-4.
118. Ognjanovic S, Yuan JM, Chaptman AK, Fan Y, Yu MC. Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA. Carcinogenesis 2009; 30: 758-762.
119. Qin H, Liu B, Shi T, Liu Y, Sun Y, Ma Y. Tumour necrosis factoralpha polymorphisms and hepatocellular carcinoma: a metaanalysis. J Int Med Res 2010; 38: 760-8.
120. Yang Y, Luo C, Feng R, Bi S. The TNF-α, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2011; 137: 947-52.
121. Wei Y, Liu F, Li B, et al. Polymorphisms of tumor necrosis factoralpha and hepatocellular carcinoma risk: a HuGE systematic review and meta-analysis. Dig Dis Sci 2011; 56: 2227-36.
122. Lee D, Chung YH, Kim JA, et al. Tumor necrosis factor-alpha promoter gene polymorphisms affect the occurrence of hepatocellular carcinoma in patients with chronic hepatitis B. J Hepatol 2010; 52: S223-4. [Abstract]
123. Kim SE, Lee D, Chung YH, et al. Tumor necrosis factor-alpha promoter gene polymorphism in relation to recurrence of hepatocellular carcinoma following complete remission by locoregional therapy. J Hepatol 2012; 56: S397. [Abstract]
124. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996; 274: 782-4.
125. Kyle S, Chandler D, Griffiths CE, et al.; British Society for Rheumatology Standards Guidelines Audit Working Group (SGAWG). Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology (Oxford) 2005; 44: 390-7.
126. Taylor PC. Antibodytherapy for rheumatoid arthritis. Curr Opin Pharmacol 2003; 3: 323-8.
127. Osterman MT, Lichtenstein GR. Current and FutureAnti-TNFTherapy for Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2007; 10: 195-207.
128. van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 2006; 11: 397-408.
129. Manusama ER, Stavast J, Durante NM, Marquet RL, Eggermont AM. Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approach. Eur J Surg Oncol 1996; 22: 152-7.
130. Manusama ER, Nooijen PT, Stavast J, Durante NM, Marquet RL, Eggermont AM. Synergistic antitumor effect of recombinant human tumor necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg 1996; 83: 551-5.
131. Ruggiero V, Latham K, Baglioni C. Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells. J Immunol 1987; 138: 2711-7.
132. Watanabe N, Niitsu Y, Yamauchi N, et al. Synergistic cytotoxicity of recombinant human TNF and various anti-cancer drugs. Immunopharmacol Immunotoxicol 1988; 10: 117-27.
133. Watanabe N, Niitsu Y, Umeno H et al. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 1988; 48: 2179-83.
134. Ryu SH. Angiogenic factors in HCC. In Chung YH Ed. Systemic anticancer therapy for hepatocellular carcinima. Jin Publishing Co. 2011: 39-59.
135. Ryu SH, Chung YH, Lee H, et al. Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma. Hepatology 2008; 47: 929-36.
136. Lee H, Ryu SH, Hong SS, et al. Overexpression of metastasisassociated protein 2 is associated with hepatocellular carcinoma size and differentiation. J Gastroenterol Hepatol 2009; 24: 1445-50.
137. Bellavance EC, Alexander HR Jr. TNF-based isolated hepatic perfusion. Front Biosci 2009; 14: 1771-84.
138. Feldman ED, Wu PC, Beresneva T, et al. Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. J Gastrointest Surg 2004; 8: 200-7.
139. Verzaro R, Zeh H, Bartlett D. A safe and fast technique for isolated hepatic perfusion. J Surg Oncol 2008; 98: 393-6.
140. Yamamoto A, Sato T. Locoregional treatment of malignant hepatic tumors with biologic response modifiers. Surg Oncol Clin N Am 2008; 17: 935-55.
141. Vahrmeijer AL, van de Velde CJ, Hartgrink HH, Tollenaar RA. Treatment of melanoma metastases confined to the liver and future perspectives. Dig Surg 2008; 25: 467-72.
142. Boone BA, Bartlett DL, Zureikat AH. Isolated hepatic perfusion for the treatment of liver metastases. Curr Probl Cancer 2012; 36: 27-76.
143. Ryu SH, Chung YH. How to overcome multidrug resistance in chemotherapy for advanced hepatocellular carcinoma. Liver Int 2010; 30: 496-8.
144. Shibata H, Yoshioka Y, Ikemizu S, et al. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window. Clin Cancer Res 2004; 10: 8293-300.
145. Lucas R, Montesano R, Pepper MS, et al. Lectin-deficient TNF mutants display comparable anti-tumor but reduced pro-metastatic potential as compared to the wild-type molecule. Int J cancer 2001; 91: 543-9.
146. Li G, Dong S, Qu J, et al. Synergism of hydroxyapatite nanoparticles and recombinant mutant human tumor necrosis factor-a in chemotherapy of multidrug-resistant hepatocellular carcinoma. Liver Int 2010; 30: 585-92.